



UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-192)

1645  
RECEIVED

SEP 30 2002

PATENT TECH CENTER 1600/2900

In the Application of: )

Progulske-Fox, et al. )

Serial No.: 09/849,115 )

Filed: May 5, 2001 )

For: Methods and Compositions for )  
Angioproliferative Disorder Treatment )

Art Unit: 1645

Examiner: To be assigned

TRANSMITTAL LETTER

Asst. Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:

- a) Second Supplemental Information Disclosure Statement;
- b) PTO Form 1449 and one (1) cited reference;
- c) Return postcard

2. With respect to fees:


- a) It is believed no fee is due at this time.
- b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on September 20, 2002.

Date: September 20, 2002

Respectfully submitted,

  
Lisa M.W. Hillman

Registration No. 43,673



UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-192)

IDS/ #12  
RECEIVED  
10/29/02  
SEP 30 2002  
TECH CENTER 1600/2900

PATENT

In the Application of: )  
)  
    **Progulske-Fox, et al.** )  
)      Art Unit: 1645  
Serial No.:    09/849,115 )  
)      Examiner: To be assigned  
Filed:    May 5, 2001 )  
)  
For:    **Methods and Compositions for** )  
      **Angioproliferative Disorder Treatment** )

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

In the judgment of the undersigned, portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any

importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

#### **CITED REFERENCES**


##### **Other Documents**

1. Potempa, et al., "*The Multiple Forms of Trypsin-like Activity Present in Various Strains of Porphyromonas gingivalis are due to the Presence of either Arg-Gingipain or Lys-Gingipain*", *Infection and Immunity*, Vol. 63, No. 4, pp. 1176-1182, 1995

Respectfully submitted,

Date: September 20, 2002

by:



**Lisa M.W. Hillman**

Reg. No. 43,673